Description
Abstract We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cf...
| Date made available | 2022 |
|---|---|
| Publisher | figshare |
Research output
- 1 Article
-
Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
Vrba, L., Futscher, B. W., Oshiro, M., Watts, G. S., Menashi, E., Hu, C., Hammad, H., Pennington, D. R., Golconda, U., Gavini, H., Roe, D. J., Shroff, R. T. & Nelson, M. A., Dec 2022, In: Clinical Epigenetics. 14, 1, 28.Research output: Contribution to journal › Article › peer-review
Open Access19 Link opens in a new tab Scopus citations
Cite this
- DataSetCite